Member Info for BuenaVista

Too many things to detail here without screenshots, but take the webpage https://avacta.com/precision/3rd-gen-affdc/

3rd Gen AffDC, but the title on the page is 'Third Generation pre|CISION® Peptide Drug Conjugate' and the link to it from the pipeline page says '3rd Gen - Biologic Conjugate Drug'

So is it AffDC, PDC or BCD? Inconsistent.

And on the Pipeline page, many errors, including no explanation on the page of what the D-Ala-Pro peptide is:

> Alternate capping group with PEG links to enhance plasma protein binding and extend half-life of the *preCISION®* molecule (*t1/2*of* hours in plasma)

> *Self-immolativelinker* allows additional *warheadchemistry* to link to *the D-Ala-Pro peptide*

@Bella, the answer is lack of funds to pursue all the possibilities in-house. Which is why there is only ONE new candidate in the pipeline - AVA6103.

Avacta will take AVA6000 to regulatory approval for STS and/or SGC and hope to license it out for triple negative breast cancer.

Avacta hope that AVA6103 will be licensed out for breast cancer and gastric, lung, pancreatic and possibly other cancers - all diseases that are big markets, so attractive to big farmer, but would require multiple, multiple clinical trials for combination therapies if AVA6103 monotherapy proves not to result in 100% remission.

There are also possibly other candidates with payloads in the AVA6100 series. AVA6103 is the third numbered candidate in the series. The others may have exatecan (with different capping group and/or self-immolative linker) and certainly other warheads as their payload. Unless Avacta identifies one suitable for development and has the funds available by that time to take it to market, then these will all be available for licensing.

The AVA7100 series, the AffDCs, are a whole new ball game, but very early days still. No individual drug candidate(s) have been identified yet (that we know of).

Wow. Website content is all over the place with formatting, wording and spelling errors. Looks unprofessional.

Have they even had a breast cancer patient on the trial?

It doesn't matter whether they have or not. AVA6000 works (proof of concept) and Phase 1b will test for efficacy in breast cancer.

A collection of assets in an indication (specific, narrow uses, e.g. breast cancer) or therapeutic area (general, broad uses, e.g. cancer).

^means more than one

Correct Timmy, in this context a franchise means than one approach/moa in an indication/therapeutic area.

If a company has an interest and more than one product in say allergies, then that company could be said to have an allergy franchise.

Avacta never said a pipeline of 10. That was a misreading by overenthusiastic investors.

What is new is the statement that AVA7100 is the research code series for AffDCs and the mention for the market (that is, in an RNS and not just on the website) that the interest in breast cancer extends beyond AVA6103 (to include AVA6000: that is, a 'franchise').

Well AVCT, you sounded so sure that "the bulk of P2 will take place" in America. But in reality, you just made it up.

@AVCT, do you know for sure that the bulk of Phase 2 will take place in the US?

I'm looking forward to the 'FAP-Dox (AVA6000): Current status and Path Forward' session as there should be more meat on that, even if it does come with a lower case of status.

"oh and by the way 100 x 25k happens to be £25 mill. Do the math"

Never mind the no new pipeline drugs. That was a given. What about the old pipeline drugs that have gone from the old pipeline list? Are they all now of no value whatsoever? They may well now be sunk costs but it's still a question that needs to be asked.

As well as a clear indication of funding intentions and timelines for the PDC and AffDC programs, I'd like to know why the partnerships with LG Chem and Daewoong are no longer listed on the Pipeline page. Are they still active? If so, why not listed?

https://web.archive.org/web/20240523004059/https://avacta.com/pipeline/

What is the plan for AVA3996? Has it just been dropped completely (they can say that) or is it available for licensing (they probably can't say that)?

How about the Affimer candidates AVA028 / 032 and AVA021? Is there any value left in them? Are pure Affimer drugs now consigned to the dustbin of history?

And is the licence deal with POINT, now with Eli Lilly, still active?

Pretty sure patients can waive their right to annonymity if they want to and the company wants publicity. Theragnostics is now owned by a private German company. Probably looking to raise money to put ATT001 through Phase 2 and 3.

Drug candidate is ATT001

Company is Theragnostics Ltd

Trial is https://clinicaltrials.gov/study/NCT06650605

Relevance to Avacta is zero

Any corruption. No doubt the law already covers some, such as the SFO investigating that Unite hotel, but what the law doesn't tackle is the 'elite' fraud and corruption of the rich and powerful.

@seethreeIPO, I'm surprised you still go for that trickle down economics of the rich and corrupt, given how we see it playing out here on AIM and with Avacta shares as a good example of market manipulation by those with the inside knowledge and money to play the market with.

I'm no Labour supporter but I find it hard to believe they'll be any more of a car crash than the Conservatives and their rich mates have been. What I'd really appreciate though would be a clamp down on corruption.

Fourteen years of Conservative government and four months of Labour government. Just saying.

True, but not according to the Corporate Governance page: https://avacta.com/investors/corporate-governance/

"Tony Gardiner was appointed as an Executive Director in January 2016 and fulfils the role of Chief Financial Officer for the Group. Tony has over 25 years’ experience in senior financial and operational roles across small and large organisations and has previously served as CFO in an AIM-listed business. In addition to this role, Tony is also Company Secretary and provides advice and guidance to the Board and Non-executive Directors. The Board acknowledges that best corporate governance practice would not combine the role of an Executive Director and Company Secretary; however, given the relative size of the Group at this stage, the Board is comfortable with Tony performing both roles but will review the position as the Group grows. Tony’s time commitment is full time."